Dr Rajesh K. Singh

CSO & Managing Director

India’s CDMO sector is at a turning point, rapidly emerging as a global hub for high-quality, cost-efficient drug development and manufacturing. Valued at $7- 22 billion today and projected to reach $15-50 billion by the decade’s end, this growth is driven by India’s skilled workforce, strong regulatory track record and rising demand for generics and biosimilars. Post-pandemic supply chain shifts, government incentives like the PLI scheme and investments in advanced manufacturing are further accelerating this momentum.

However, growth also brings pressing complexity. So to say, pharma, nutraceutical and cosmeceutical players face stricter regulatory requirements, soaring R&D costs, compressed timelines and pressure to differentiate in competitive markets. Additionally, supply chain volatility and challenges such as bioavailability, stability and global compliance make product launches even tougher.

This is where Dosage Life Sciences (DLS) transforms these challenges into opportunities. Its innovation-led approach helps clients design differentiated products, develop globally compliant dossiers and accelerate market entry by cementing its reputation as a trusted partner in a fast-evolving global pharma ecosystem.

Scaling New Heights

Founded by industry veteran Dr. Rajesh K. Singh, CSO & Managing Director, DLS has rapidly grown from a consultancy into a full-spectrum CRDO and CDMO platform. The company was registered in 2022 but started functioning since August 2024. Known for its scientific rigor, regulatory expertise and customer-centric approach, it provides end-to-end support across formulation development, regulatory compliance, analytical services and commercial manufacturing.

Rather than owning manufacturing or R&D infrastructure, the company holds a strategic partnership model, collaborating with clients and leveraging a robust network of WHO, FDA, MHRA and Schedule M-compliant manufacturing facilities and NABL-accredited, DSIRrecognized research laboratories.

This asset-light approach allows the company to deliver high-quality, globally compliant pharmaceutical solutions with agility and cost-efficiency. “Trust, Transparency and Scientific Excellence are our DNA at DLS”, states Dr Rajesh K. Singh, CSO & Managing Director, DLS.

DLS's portfolio spans diverse therapeutic areas, including cardiovascular, anti-diabetic, dermatology, respiratory, neurology, pain management, nutrition, oncology-supportive care and personalized medicine. Additionally, the company’s strategic collaborations with Theon Pharmaceuticals, Mint Life Sciences, Bharat Sterile and Ashta Bandhu Agri India have strengthened capabilities in sterile manufacturing, nutraceuticals and biotech.

Currently, the company is expanding its geographic presence by supporting dossiers for product launches in the US, EU and Africa. Investments in R&D and partner facilities have also enabled diversification into baby care with the Tiny Treasures range, further positioning the company for sustainable global impact.

Tech-Led Transformation

DLS is driving digital transformation across its operations by integrating AI-assisted formulation design, digital quality systems and automated workflows. These innovations reduce human error, shorten development cycles and ensure robust regulatory compliance, giving clients faster submissions and speed-to-market advantages.

Its AI-enabled predictive analytics in stability studies and process optimization minimizes waste and boosts efficiency. Automation in sterile manufacturing improves precision, while ERP and SAP systems streamline supply chains. Additionally, its Partnerships with technology providers enable real-time monitoring, enhancing operational efficiency by up to 25 percent and supporting the development of innovative drug delivery systems.

Sustainable Innovation

For DLS, sustainability is a core principle, not an option. The company integrates green chemistry, eco-efficient operations, waste reduction and energy optimization into every stage of its processes. From eco-friendly packaging and water conservation to energy-efficient technologies, the company minimizes environmental impact while supporting clients’ ESG objectives.

Furthermore, its focus on sustainable API manufacturing and biodegradable packaging aligns with global green standards, appealing to eco-conscious partners and reinforcing its commitment to responsible innovation.

Driving Client Success

DLS emphasizes that today’s clients must accelerate timeto- market while upholding the highest quality, especially for sterile injectables and advanced delivery systems. In total, the company acts as an extension of client labs, offering comprehensive CMC support from pre-formulation through stability studies. This integrated approach can reduce development timelines by up to 30 percent.

Through partnerships with NABL-approved labs, it ensures rigorous testing and compliance with global standards. Its expertise in handling potent formulations addresses critical safety requirements. In nutraceuticals, the company focuses on natural ingredient sourcing and enhanced bioavailability.

For cosmeceuticals, it prioritizes skin-friendly, eco-conscious formulations. By combining technical expertise with agility, DLS helps clients navigate postpandemic supply challenges, regulatory complexity and product differentiation needs. This ultimately accelerates innovation and ensures successful market launches.

A Robust Future Roadmap

DLS has been devising a strong future roadmap with strategic moves into high-potency APIs, niche intermediates and supply chain integration to enhance reliability and competitiveness. It is strengthening its CDMO offerings in lifecycle management, technology transfer and dossier developments while forming global partnerships to expand market reach.

Investments in AI, automation and digital infrastructure are laying the foundation for next-generation biologics facilities and AI-driven research and development. With a growing focus on digital healthcare, automation and blockchain solutions, the company mirrors India’s shift from cost-led outsourcing to innovation-led global partnerships. By combining scientific rigor, customer-centric values and a commitment to sustainability, DLS stands as one of India’s most promising CDMOs by driving global health impact and shaping the future of pharmaceutical development.